Last reviewed · How we verify
NCT05438589
Novel Rapid POC Diagnostics for COVID-19
trial in COVID-19 Respiratory Infection in 1,283 participants. Completed in 28 February 2023.
28 February 2023
Quick facts
| Lead sponsor | Foundation for Innovative New Diagnostics, Switzerland |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,283 |
| Start date | 25 April 2022 |
| Primary completion | 28 February 2023 |
| Estimated completion | 28 February 2023 |
| Sites | 2 locations across Georgia, South Africa |
Conditions studied
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
Sponsor
Foundation for Innovative New Diagnostics, Switzerland
Who can join
Adults 18 to 100, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicentre study in which the diagnostic accuracy of multiple Covid-19 Antigen rapid diagnostic tests will be assessed for COVID-19 case detection using prospectively collected nasal swabs and saliva samples from participants suspected to have Covid-19 infection (with or without symptoms). The study will last approximately 9 months.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05438589
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Respiratory Infection
Currently open trials in the same condition.
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting
Other Foundation for Innovative New Diagnostics, Switzerland trials
Trials by the same sponsor.
- NCT06213051 — Comparison of Self-collection Using Dry Compared to Wet Swabs for HPV Detection · unknown
- NCT05944731 — Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in Kenya. · NA · unknown
- NCT06118749 — Leishmania Antigen Rapid Diagnostic Test Proof-of-Concept and Validation Study · terminated
- NCT05944718 — Use of Continuous Glucose Monitoring Devices Among People Living With Type 1 Diabetes in South Africa · NA · completed
- NCT06170515 — BGM and HbA1c POC Device Evaluation · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05438589 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Foundation for Innovative New Diagnostics, Switzerland
- Last refreshed: 1 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05438589.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing